•
Sep 30, 2021

SIGA Technologies Q3 2021 Earnings Report

SIGA Technologies reported a net loss and decrease in revenue compared to the same quarter last year, but anticipates significant TPOXX deliveries in Q4.

Key Takeaways

SIGA Technologies reported a challenging third quarter with a net loss of $3.1 million and total revenues of $4.8 million, a significant decrease from the $44.3 million in revenue and $24.2 million net income reported in the same period last year. However, the company anticipates delivering up to $113 million of oral TPOXX to the U.S. government in the fourth quarter. The company also repurchased 1.1 million shares for $7.1 million during the quarter.

SIGA reported a net loss of $3.1 million, or $0.04 per share, compared to a net income of $24.2 million, or $0.31 per share, in Q3 2020.

Total revenues for Q3 2021 were $4.8 million, a decrease from $44.3 million in Q3 2020.

The company expects to deliver up to approximately $113 million of oral TPOXX to the U.S. government in Q4 2021.

SIGA repurchased 1.1 million shares of its common stock for $7.1 million during the third quarter of 2021.

Total Revenue
$4.85M
Previous year: $44.3M
-89.1%
EPS
-$0.04
Previous year: $0.31
-112.9%
Shares Repurchased
1.1M
Previous year: 900K
+22.2%
Gross Profit
$1.53M
Previous year: $36.6M
-95.8%
Cash and Equivalents
$92.8M
Previous year: $78.7M
+18.0%
Total Assets
$136M
Previous year: $141M
-4.1%

SIGA Technologies

SIGA Technologies

SIGA Technologies Revenue by Segment

Forward Guidance

SIGA Technologies anticipates delivering up to approximately $113 million of oral TPOXX to the U.S. government in the fourth quarter of 2021.

Positive Outlook

  • Delivery of up to approximately $113 million of oral TPOXX to the U.S. government in the fourth quarter of 2021.
  • Strong and growing revenue base of TPOXX.
  • Continuing importance in orthopox health security preparedness.
  • BARDA exercised a procurement option under the 19C BARDA contract for the delivery of oral TPOXX.
  • New share repurchase authorization allows for repurchasing up to $50 million of common stock.

Challenges Ahead

  • COVID-19 pandemic may continue to delay the timing of international contract awards for oral TPOXX.
  • The COVID-19 pandemic could result in a slower pace of product deliveries if the pandemic results in shortages or delays in the receipt by the supply chain of raw materials.
  • Executive Order 14042 could have a material impact on the availability and/or timing of services provided to SIGA by certain vendors for supply chain activities and research and development activities.
  • Pandemic could have an impact upon the broader macro environment or the Company’s industry.
  • Company reported a net loss of $3.1 million for the third quarter.

Revenue & Expenses

Visualization of income flow from segment revenue to net income